HFpEF is not Just an LV Disease
It’s Also an Atrial Dysfunction Disease
A Vicious Cycle of Electromechanical Breakdown
HFpEF involves significant left atrial (LA) remodeling, mechanical dysfunction, and chronically elevated LA pressures.
These atrial abnormalities contribute to impair ventricular filling, reduced cardiac output, and symptom burden.
The Missing Link: Atrial Synchrony
Loss of synchronized atrial contraction impairs left ventricular filling and raises atrial pressures—driving congestion, fatigue, and repeat hospitalizations. Traditional treatments—drugs, ablation—target symptoms, not the electromechanical cause.
Maxwell Biomedical Is Restoring the Rhythm of the Heart
Rhythm360: First-in-Class AI-Driven CRT-A Platform for Atrial Resynchronization
(Atrial Function Optimization)
A non-destructive, AI-driven implantable system, Rhythm360 restores sinus rhythm and reestablishes biatrial synchrony—without damaging tissue. It’s the first cardiac rhythm therapy specifically designed to improve hemodynamics in patients with AF and HFpEF.
Rhythm360 is to the atria what CRT was to the ventricles—restoring synchrony to improve heart failure outcomes.
Maxwell Biomedical is closing the therapeutic gap for HFpEF-AF patients—where no rhythm control device exists today.
-
Exciting News from MaxWell Biomedical!
Maxwell Biomedical is expanding its ongoing clinical study to further validate the groundbreaking Spatial Resynchronization Therapy (SRT) for patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF).
SRT is designed to imperceptibly terminate AF and restore atrial function and atrial synchrony —a non-destructive, next-generation approach that sets it apart from conventional ablation therapies. With this expansion, we aim to accelerate clinical insights, broaden patient access, and drive a paradigm shift in AF treatment for the AF-HFpEF population.
Why It Matters:
· Better Outcomes – SRT enhances atrial heart function while preventing AF, addressing a critical unmet need.
· Expanded Study Scope – More patients, more data, stronger clinical validation.
· Innovative Non-Destructive Approach – Unlike ablation, SRT does not destroy cardiac tissue but restores atrial conduction.
As we take this next step, we’re grateful for our investors, clinical partners, and dedicated team members working to bring a new era of AF treatment to patients worldwide.
Stay tuned for more updates!
March 13, 2025
Active Atrial Fibrillation Management
Transforming AF Care: A Device Approach That Overcomes Past Limitations
Maximum Wellness
[ mak-suh-muhm ] [ wel-nis ]
Decades of AF Treatment Have Focused Soley on Tissue Destruction
Medicine Evolves: 🟥 Cox-Maze Surgery (1980s) →🟧 Catheter Ablation (1990s–Present) →🟩 Non-destructive (Future)